Pemtumomab
| Monoclonal antibody | |
|---|---|
| Source | Mouse |
| Target | MUC1 |
| Clinical data | |
| Trade names | Theragyn |
| Intraperitoneal | |
| Identifiers | |
 | |
| None | |
| Chemical data | |
 (what is this?) (verify) | |
Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour.[1] As of 2009, it is undergoing Phase III clinical trials.[2]
It has been granted orphan drug status in Europe.[3]
References
- ↑ Oei, AL; Moreno, M; Verheijen, RH; Sweep, FC; Thomas, CM; Massuger, LF; Von Mensdorff-Pouilly, S (2008). "Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer". International Journal of Cancer. Journal International Du Cancer 123 (8): 1848–53. doi:10.1002/ijc.23725. PMID 18661524.
- ↑ ClinicalTrials.gov
- ↑ Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status